TRAEs led to the interruption of any study treatment compound in 24 (42.9%) patients, primarily due to decreased neutrophil count (5 patients [8.9%]), increased alanine aminotransferase (ALT) (4 [7.1%]), asthenia (4 [7.1%]), and decreased WBC count (3 [5.4%]). This evidence concerns the gene GPT and asthenia.